## **Product** Data Sheet

## FR194921

Cat. No.: HY-116800 CAS No.: 202646-80-8 Molecular Formula:  $C_{23}H_{23}N_5O$  Molecular Weight: 385.46

Target: Adenosine Receptor
Pathway: GPCR/G Protein

Storage: Powder -20°C 3 years

In solvent -80°C 6 months

-20°C 1 month

## **BIOLOGICAL ACTIVITY**

Pescription FR194921 is a potent, selective and orally active and cross the blood-brain barrier Adenosine A1 antagonist with K<sub>i</sub> value of 6.6, 5400 nM for A1, A2A, respectively. FR194921 shows cognitive-enhancing and anxiolytic activity<sup>[1][2]</sup>.

IC<sub>50</sub> & Target A1R A<sub>2A</sub>R 6.6 nM (Ki) 5400 nM (Ki)

In Vivo FR194921 (32 mg/kg; p.o.) shows good oral bioavailability with AUC of 6.91  $\mu$ g·h/mL,  $C_{max}$  of 2.13  $\mu$ g/mL and  $T_{max}$  OF 0.63 h, BA of 60.6% in rats<sup>[1]</sup>.

FR194921 (0.032, 0.1, 0.32 mg/kg; p.o.) dose-dependently attenuates the hypolocomotion induced by CPA (HY-103181) $^{[2]}$ . FR194921 (0.1-10 mg/kg; i.p.) significantly ameliorates scopolamine (HY-N0296)-induced memory deficits $^{[2]}$ .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	SD rats <sup>[2]</sup>
Dosage:	0.032, 0.1, 0.32 mg/kg
Administration:	P.o.; administered orally 25 min prior to intraperitoneal administration of CPA (0.056 mg/kg; i.p.)
Result:	Dose-dependently attenuated the hypolocomotion induced by CPA with an ED50 value of 0.08 mg/kg and statistical significance at 0.32 mg/kg.
	[6]
Animal Model:	SD rats <sup>[2]</sup>
Dosage:	0.1, 0.32, 1, 3.2, 10 mg/kg
Administration:	I.p.; Scopolamine (HY-N0296)(1 mg/kg, i.p.)
Result:	Significant cognitive enhanced following scopolamine-induced memory deficits in rats.

## **REFERENCES**

[1]. Kuroda S, et al. Design, synthesis and biological evaluation of a novel series of potent, orally active adenosine A1 receptor antagonists with high blood-brain barrier permeability. Chem Pharm Bull (Tokyo). 2001 Aug;49(8):988-98.
[2]. Maemoto T, et al. Pharmacological characterization of FR194921, a new potent, selective, and orally active antagonist for central adenosine A1 receptors. J Pharma Sci. 2004 Sep;96(1):42-52.

 $\label{lem:caution:Product} \textbf{Caution: Product has not been fully validated for medical applications. For research use only.}$ 

Tel: 609-228-6898 Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com